Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMCPR: Vasopressin for Cardiac Arrest
NCT03191240Phase 2Completed
- Sponsor
- Asan Medical Center
- Start
- Dec 2017
- Primary completion
- Aug 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vasopressin in cardiac arrest (SCA) (2 arms), sponsored by Asan Medical Center. Primary endpoint: Sustained Return of Spontaneous Circulation at 20 minutes. Started Dec 2017; status: completed.
02
Drugs
vasopressin
03
Conditions
cardiac arrest (SCA)
Beyond the preview
Go deeper on NCT03191240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03191240.